Stockreport

Dynavax Reports Interim Analysis of Ongoing Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

Dynavax Technologies Corporation  (DVAX) 
Last dynavax technologies corporation earnings: 3/11 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.dynavax.com
PDF Demonstrated seroprotection rate of 86.4% at week 20 after 4 standard doses of HEPLISAV-BSafety data showed HEPLISAV-B was well toleratedCompany to host webinar review o [Read more]